Elutia (NASDAQ:ELUT – Get Free Report) and Teleflex (NYSE:TFX – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
Risk & Volatility
Elutia has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Teleflex has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Earnings & Valuation
This table compares Elutia and Teleflex”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Elutia | $12.29 million | 3.27 | $53.38 million | $1.11 | 0.81 |
| Teleflex | $1.99 billion | 3.22 | -$905.64 million | $8.23 | 19.64 |
Elutia has higher earnings, but lower revenue than Teleflex. Elutia is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings for Elutia and Teleflex, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Elutia | 1 | 0 | 0 | 0 | 1.00 |
| Teleflex | 0 | 6 | 5 | 1 | 2.58 |
Teleflex has a consensus price target of $163.30, suggesting a potential upside of 1.05%. Given Teleflex’s stronger consensus rating and higher possible upside, analysts clearly believe Teleflex is more favorable than Elutia.
Profitability
This table compares Elutia and Teleflex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Elutia | 546.70% | -140.53% | -54.54% |
| Teleflex | 13.51% | 10.57% | 4.96% |
Institutional & Insider Ownership
74.0% of Elutia shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 17.8% of Elutia shares are held by insiders. Comparatively, 0.7% of Teleflex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Teleflex beats Elutia on 10 of the 15 factors compared between the two stocks.
About Elutia
Elutia is a medical technology company focused on developing biologic products for use in surgery. Its portfolio includes envelopes designed to support cardiac implantable electronic devices, such as pacemakers and defibrillators. The company’s products include CanGaroo, an extracellular-matrix envelope designed to help secure and support implanted devices, and EluPro, an antibiotic-eluting envelope intended to help reduce the risk of infection associated with these devices. Elutia was formerly known as Aziyo Biologics and adopted its current name in 2023 as it focused its business on drug-eluting biologic technologies.
About Teleflex
Teleflex is a global medical technology company that develops, manufactures and markets single-use medical devices used by healthcare professionals in hospitals and other care settings. Its products support a range of procedures, including vascular access, anesthesia, critical care, surgery, urology and emergency medicine. The company’s offerings include vascular and interventional access devices, catheters, airway management products, surgical instruments and other devices used in diagnostic and therapeutic procedures.
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
